Testosterone Undecanoate

Testosterone undecanoate therapy may not confer long-term benefits for men with impaired glucose tolerance and normal testosterone levels, according to a follow-up survey of participants in the T4DM trial.

The FDA has approved an oral testosterone undecanoate softgel for men with deficiency or absence of endogenous testosterone, or hypogonadism, according to a press release.

Men prescribed long-acting testosterone undecanoate injections had a higher adherence to therapy at 1 year compared with those receiving short-acting testosterone cypionate injections, according to study findings.

The FDA has given final approval for an oral testosterone undecanoate therapy for men with a deficiency or absence of endogenous testosterone or hypogonadism, according to an industry press release.

Given the prevalence of overt thyroid disease in the U.S., Alex Stagnaro-Green, MD, MHPE, regional dean at the University of Illinois College of Medicine in Rockford, said that universal thyroid screening is warranted during pregnancy.

Testosterone undecanoate injected at 8-week intervals for men with hypogonadism may reduce fluctuations and increase mean testosterone levels compared with a 10-week dose regimen, according to data from a modeling study.

Two-year therapy with testosterone undecanoate normalized serum testosterone levels and reduced nonalcoholic fatty liver disease grade among men with obesity, functional hypogonadism and type 2 diabetes, data show.

Oral testosterone undecanoate is an effective long-term therapy for men with hypogonadism, with a safety profile that is similar to other approved testosterone formulations, data from an extension study show.

The FDA accepted a new drug application for an oral testosterone undecanoate softgel for the treatment of primary and secondary hypogonadism in men, according to a press release from Marius Pharmaceuticals.

Compared with placebo, 2 years of testosterone therapy was associated with lower risk for type 2 diabetes among men with impaired glucose tolerance or newly diagnosed diabetes but no hypogonadism, according to trial data.